Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.
スポンサーリンク
概要
- 論文の詳細を見る
To investigate the central and regional hemodynamics after long-term administration of CS-905, a novel calcium blocker, we administered the agent (1 and 3 mg/kg/day) for 15 weeks in spontaneously hypertensive rats. At the end of the dosing period, hemodynamic changes were examined using the radioactive microsphere technique. CS-905 produced a sustained dose-dependent antihypertensive effect without inducing tolerance during the 1 5-week dosing period and prevented cardiac hypertrophy. The agent increased cardiac output, decreased blood pressure and thus decreased total peripheral resistance in a dose-related manner. Regional blood flows measured by the microsphere technique were increased in the kidney and brain despite the lowered blood pressure. There was no organ where regional blood flow was decreased. These changes after chronic treatment with CS-905 would be beneficial in the long-term therapy of hypertension.
- 公益社団法人 日本薬理学会の論文
著者
-
SHIGA Hiroshi
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
OIZUMI Kiyoshi
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
NISHINO Hiroshi
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
MIYAKE Shigeki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
SADA Toshio
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
MIYAMOTO Masaaki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Research Laboratories, Sankyo Co., Ltd.
-
OIZUMI Kiyoshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
NISHINO Hiroshi
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
SADA Toshio
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
-
KOIKE Hiroyuki
Sankyo Biological Reseach Laboratories, Sankyo Co., Ltd.
関連論文
- Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium blocker, in conscious SHR.
- Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
- Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
- Beneficial renal effects of CS-905, a novel dihydropyridine calcium blocker, in SHR.